FDA Brief

Warning letters Drugs

FDA warning letter to

HydraMed IV LLC dba HydraMed

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

What happened

FDA reviewed HydraMed's website, https://hydramed.com, in March 2026 and found it offers compounded semaglutide and tirzepatide products. The site's product labels show "HydraMed" as if HydraMed made the drugs, when it does not, and the site says the products come from an "FDA-approved pharmacy." FDA says both claims are false or misleading, which makes the drugs misbranded.

What FDA found

  1. The website labels show "HydraMed" as the maker of the compounded semaglutide and tirzepatide, but HydraMed is not the compounder, so the labels mislead buyers about who made the drugs.

    FD&C Act section 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)
  2. The website says the compounded products come from an "FDA-approved pharmacy," but FDA does not approve or license pharmacies or outsourcing facilities, so the claim implies a government approval that does not exist.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]
  3. Because of these false or misleading claims, the compounded drugs are misbranded and shipping them across state lines is a prohibited act.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA tells HydraMed to find the root causes, fix the website claims, and send a written response with the steps taken and supporting documents. The response is due within 15 business days, and FDA also asks for the names of the entities that actually make the compounded drugs plus a sample of their labeling.

Who should pay attention

  • telehealth and med-spa companies marketing compounded semaglutide or tirzepatide
  • compounding pharmacies and outsourcing facilities that supply such platforms
  • marketing and regulatory teams that write product pages and labels for compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low